Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of DCC-2618 in advanced malignancies
NL-OMON55457Phase 1Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ripretinib in gastrointestinal stromal tumor (GIST), systemic mastocytosis (SM), mast cell leukemia (MCL) and 7 more (4 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Safety and tolerability, Maximum tolerated dose and recommended Phase 2 dose and 1 more. Started May 2018; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)systemic mastocytosis (SM)mast cell leukemia (MCL)hypereosinophilic syndrome (HES)chronic eosinophilic leukemia (CEL)
Beyond the preview
Go deeper on NL-OMON55457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55457.